Nippon Boehringer Ingelheim Initiates Phase II Trial For Hepatitis C Drug
This article was originally published in PharmAsia News
Executive Summary
Nippon Boehringer Ingelheim starts Phase II trials in Japan for BI201335, an antiviral agent for patients with chronic hepatitis C